M
Marlo Whitehead
Researcher at Queen's University
Publications - 83
Citations - 4386
Marlo Whitehead is an academic researcher from Queen's University. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 20, co-authored 72 publications receiving 4080 citations. Previous affiliations of Marlo Whitehead include International Council for the Exploration of the Sea & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming-Sound Tsao,Akira Sakurada,Jean-Claude Cutz,Jean-Claude Cutz,Chang-Qi Zhu,Chang-Qi Zhu,Suzanne Kamel-Reid,Suzanne Kamel-Reid,Jeremy A. Squire,Jeremy A. Squire,Ian A. J. Lorimer,Tong Zhang,Tong Zhang,Ni Liu,Ni Liu,Manijeh Daneshmand,Paula Marrano,Paula Marrano,Gilda da Cunha Santos,Gilda da Cunha Santos,Alain E. Lagarde,Frank C. Richardson,Lesley Seymour,Marlo Whitehead,Keyue Ding,Joseph L. Pater,Frances A. Shepherd,Frances A. Shepherd +27 more
TL;DR: Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.
Journal ArticleDOI
Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer
Ming-Sound Tsao,Sarit Aviel-Ronen,Keyue Ding,Davina Lau,Ni Liu,Akira Sakurada,Marlo Whitehead,Chang-Qi Zhu,Robert B. Livingston,David H. Johnson,James R. Rigas,Lesley Seymour,Timothy Winton,Frances A. Shepherd +13 more
TL;DR: In this paper, the prognostic and predictive value of p53 gene/protein aberrations using tumor samples from JBR.10, a North American phase III intergroup trial that randomly assigned 482 patients with completely resected stage IB and II non-small-cell lung cancer (NSCLC) to receive four cycles of adjuvant cisplatin plus vinorelbine or observation alone.
Journal ArticleDOI
Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials
Timothy R. Asmis,Keyue Ding,Lesley Seymour,Frances A. Shepherd,Natasha B. Leighl,Tim Winton,Marlo Whitehead,Johanna N. Spaans,Barbara Graham,Glenwood D. Goss +9 more
TL;DR: In these large, randomized trials of systemic chemotherapy for non-small-cell lung Cancer, the presence of comorbid conditions (CCIS > or = 1), rather than age more than 65 years, was associated with poorer survival.
Journal ArticleDOI
Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy
Janet Dancey,Benny Zee,David Osoba,Marlo Whitehead,F. Lu,Leonard Kaizer,J. Latreille,Joseph L. Pater +7 more
TL;DR: Global QOL was predictive in all patients, in subgroups of patients with metastatic disease, with breast and lung cancer and other tumour types, and in patients with low global quality of life scores, patients with lows emotional functioning lived longer than did patients with high emotional functioning ratings.
Journal ArticleDOI
Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20
Andrew Arnold,Lesley Seymour,Michael Smylie,Keyue Ding,Yee Ung,B. Findlay,Christopher Lee,Marina Djurfeldt,Marlo Whitehead,Peter M. Ellis,Glenwood D. Goss,Adrien Chan,Jacinta Meharchand,Yasmin Alam,Richard Gregg,Charles Butts,Peter Langmuir,Frances A. Shepherd +17 more
TL;DR: Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer and was found to have more toxicity and required more dose modifications for gastrointestinal toxicity and rash.